CJC-1295 & Ipamorelin
CJC-1295 With DAC vs Without DAC
Reviewed by our laboratory team · Last updated 2026-07-03
CJC-1295 with DAC includes a Drug Affinity Complex (DAC) — a maleimidopropionic acid linker that covalently binds serum albumin, extending half-life to approximately one week. Without DAC (also called Modified GRF 1-29), the peptide has a plasma half-life of only about 30 minutes.
Key facts
- With DAC half-life
- ~7 days (albumin-bound)
- Without DAC half-life
- ~30 minutes
- Without DAC name
- Modified GRF 1-29 (Mod GRF 1-29)
Why the two versions
DAC prolongs exposure for weekly research administration. The non-DAC form produces a brief GH pulse mimicking physiological release, suitable for different research designs.
Quick reference
| Feature | With DAC | Without DAC |
|---|---|---|
| Half-life | ~7 days | ~30 min |
| Mechanism | Albumin binding | Free peptide |
| Also known as | CJC-1295 DAC | Mod GRF 1-29 |
Extended research context
The CJC-1295 & Ipamorelin deep dive
Deep dive: why CJC-1295 and Ipamorelin are studied together
CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release — CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.
DAC vs no-DAC: which CJC-1295 is which
'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).
Ipamorelin's selectivity profile
Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.
Research applications
- ▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
- ▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
- ▸Ghrelin-receptor binding assays for Ipamorelin analogue development
- ▸Analytical HPLC method development for lipidated GHRH analogues
- ▸Stability testing under refrigerated storage
Handling checklist
- ✓Store lyophilised at −20 °C long-term
- ✓Reconstitute in bacteriostatic water; both peptides dissolve readily
- ✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
- ✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
- ✓Do not use for human administration — research reference only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing DAC and no-DAC CJC-1295
Fix: Check the CoA — the two have very different pharmacokinetics.
✗ Assuming Ipamorelin acts on GHRH receptors
Fix: It binds the ghrelin receptor (GHS-R1a) — a separate pathway from CJC-1295.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate 2–8 °C after reconstitution.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is CJC-1295 the same as Modified GRF 1-29?
- What is the difference between DAC and no-DAC CJC-1295?
- Does Ipamorelin raise cortisol?
- Why are CJC-1295 and Ipamorelin blended together?
- How long is the half-life of CJC-1295 with DAC?
Frequently asked questions
- Which is more commonly co-studied with ipamorelin?
- The non-DAC form (Mod GRF 1-29), because both are short-acting.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab (external, rel="nofollow").
- PubMedTeichman et al., JCEM 2006pubmed.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue — Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedSinha et al., Growth-hormone secretagogues — Endocr Rev (PMID 15855273)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 (CID 16137828)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · GH-secretagogue trialsclinicaltrials.gov
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
More CJC-1295 & Ipamorelin articles
- What Is CJC-1295? Research OverviewCJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue developed by ConjuChem. Structure, DAC and non-DAC forms and research history summarised.
- What Is Ipamorelin? Research OverviewIpamorelin is a selective growth-hormone secretagogue and ghrelin-receptor agonist developed by Novo Nordisk. Structure, mechanism and research overview.
- CJC-1295 and Ipamorelin: Why They're Studied TogetherCJC-1295 (GHRH analogue) and ipamorelin (ghrelin-receptor agonist) act on complementary pathways to stimulate pulsatile growth-hormone release in research studies.
- CJC-1295 Mechanism: The GHRH AnalogueCJC-1295 mechanism: binds and activates the GHRH receptor on pituitary somatotrophs, triggering pulsatile growth-hormone release through Gαs signalling.
- Ipamorelin Mechanism: The Ghrelin ReceptorIpamorelin mechanism: selective agonist of the growth-hormone secretagogue receptor GHS-R1a (ghrelin receptor), triggering pulsatile GH release.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchWhat Is Retatrutide? Complete Research OverviewRetatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.
- GHK-Cu (Copper Peptide)What Is GHK-Cu? Copper Peptide Research OverviewGHK-Cu is a naturally occurring copper-binding tripeptide consisting of glycine, histidine, and lysine complexed with a copper(II) ion. It was discovered in 1973 by Loren Pickart and is widely studied in the peer-reviewed literature for its roles in gene expression, wound repair models, and extracellular matrix biology.
- TB-500 (Thymosin β4 fragment)What Is TB-500? Research OverviewTB-500 is a synthetic peptide corresponding to the active actin-binding region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-residue protein. It is studied in the peer-reviewed literature primarily for actin sequestration, cell migration, and angiogenesis in in vitro and animal models.
- BPC-157 (Pentadecapeptide)What Is BPC-157? Research OverviewBPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) derived from a partial sequence of a protein isolated from human gastric juice. It has been studied primarily by researchers at the University of Zagreb since the 1990s for effects on tissue repair, angiogenesis, and gastrointestinal models.
- Peptide ReferenceWhat Are Peptides? Complete GuidePeptides are short chains of amino acids connected by peptide (amide) bonds. Typically fewer than 50 residues, they occupy the middle ground between single amino acids and proteins. Peptides serve as hormones, signalling molecules, structural fragments, and — increasingly — as research and therapeutic targets.
- Bacteriostatic WaterWhat Is Bacteriostatic Water?Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a bacteriostatic preservative. The benzyl alcohol inhibits bacterial growth after the vial's initial puncture, making the same vial suitable for repeated withdrawal in research handling. It is not the same as plain sterile water.